Further Brexit Delay Avoids No-Deal Impact For Pharma – For Now
Executive Summary
The EU has given the UK another extension, this time until 31 October, to find a solution to the Brexit impasse. In the meantime, things will stay pretty much as they are for the life sciences sector, although the possibility of a no-deal exit remains if a withdrawal agreement cannot be ratified.
You may also be interested in...
Coronavirus Notebook: Italy Makes First Use Of EU’s Vaccine Export Control System, More Regulators Issue Guidance On Variants
Ukraine has established a system for issuing emergency use authorizations for COVID-19 vaccines that recognizes authorizations granted by other world regulators.
Russia’s Sputnik V COVID-19 Vaccine Starts EU Rolling Review
The Russian backers of the vaccine’s development say that if it receives a marketing authorization in the EU, distribution could begin in June this year.
Coronavirus Notebook: EU Moots Emergency Use Authorization Scheme For Vaccines, Janssen Product Up For 11 March Approval
Celltrion’s regdanvimab is undergoing an emergency use procedure in Europe, the European Medicines Agency and the health authorities in Canada have jointly published clinical data on the Moderna vaccine, and Canada has approved two versions of the AstraZeneca/Oxford University jab.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: